If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

UAE -- The U.S. Food and Drug Administration (FDA) approved lately Tirzepatide, produced by Eli Lilly, as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside diet and exercise. The SURMOUNT-OSA trial showed significant reductions in breathing ...

Leerink notes that the FDA today declared an end to the tirzepatide shortage, which “seemingly begins the process of bringing the compounded GLP-1 market back to ‘normal’ behavior.” ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA ...

Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...